Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial
Abstract Introduction Intravenous levetiracetam (IV LEV) is approved for treatment status epilepticus (SE). However, the drug’s high cost must be considered when deciding on a treatment strategy. This study aimed to compare the efficacy of brand-name and generic IV LEV for acute repetitive convulsiv...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-08-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40120-019-00150-x |
id |
doaj-a107a68c0c604739832974c19a2d10ee |
---|---|
record_format |
Article |
spelling |
doaj-a107a68c0c604739832974c19a2d10ee2020-11-25T03:46:11ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362019-08-018242543110.1007/s40120-019-00150-xCan Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled TrialRachot Wongjirattikarn0Kittisak Sawanyawisuth1Sineenard Pranboon2Siriporn Tiamkao3Somsak Tiamkao4Department of Medicine, Faculty of Medicine, and Integrated Epilepsy Research Group, Khon Kaen UniversityDepartment of Medicine, Faculty of Medicine, and North-eastern Stroke Research Group, Research Center in Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Research and Training Center for Enhancing Quality of Life of Working Age People, and Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen UniversityNursing Division, Faculty of Medicine, Srinagarind Hospital, Khon Kaen UniversityDepartment of Pharmacy, Faculty of Medicine, Khon Kaen UniversityDepartment of Medicine, Faculty of Medicine, and Integrated Epilepsy Research Group, Khon Kaen UniversityAbstract Introduction Intravenous levetiracetam (IV LEV) is approved for treatment status epilepticus (SE). However, the drug’s high cost must be considered when deciding on a treatment strategy. This study aimed to compare the efficacy of brand-name and generic IV LEV for acute repetitive convulsive seizure (ARCS) or SE. Methods Forty patients aged 18 years or older who had been diagnosed with SE or ARCS were included in this double-blind study. Patients were randomly assigned at a 1:1 ratio (via computer-generated code) to receive either brand-name or generic IV LEV. The primary outcomes were seizure control and the number of seizure exacerbations during the 24 h after drug administration, while the secondary outcomes were electroencephalographic (EEG) findings, serious adverse events, and clinical outcome at hospital discharge. Results Forty patients were randomly assigned administration with either brand-name IV LEV (10 SE and 10 ARCS patients) or generic IV LEV; 7 SE and 13 ARCS patients). There was no significant difference in patients’ baseline characteristics. The seizure control rate was 75% in the brand-name IV LEV group and 65% in the generic IV LEV group (p value: 0.490). Five (25%) patients in the brand-name IV LEV group, and six (30%) patients in the generic IV LEV group developed seizure exacerbations within 24 h after drug administration (p value 0.723). There were no reports of drug-related adverse events. Two of the patients taking brand-name IV LEV and one taking the generic IV LEV died (p value > 0.999). Conclusion Treatment with the generic IV LEV had comparable outcomes with brand-name IV LEV. The generic IV LEV may be an alternative medication for the treatment of SE and ARCS to reduce treatment costs. Trial Registration TCTR20190513001. Funding Great Eastern Drug Company.http://link.springer.com/article/10.1007/s40120-019-00150-xAcute repetitive seizuresLevetiracetamFocale®Keppra®Status epilepticus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rachot Wongjirattikarn Kittisak Sawanyawisuth Sineenard Pranboon Siriporn Tiamkao Somsak Tiamkao |
spellingShingle |
Rachot Wongjirattikarn Kittisak Sawanyawisuth Sineenard Pranboon Siriporn Tiamkao Somsak Tiamkao Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial Neurology and Therapy Acute repetitive seizures Levetiracetam Focale® Keppra® Status epilepticus |
author_facet |
Rachot Wongjirattikarn Kittisak Sawanyawisuth Sineenard Pranboon Siriporn Tiamkao Somsak Tiamkao |
author_sort |
Rachot Wongjirattikarn |
title |
Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial |
title_short |
Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial |
title_full |
Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial |
title_fullStr |
Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial |
title_full_unstemmed |
Can Generic Intravenous Levetiracetam Be Used for Acute Repetitive Convulsive Seizure or Status Epilepticus? A Randomized Controlled Trial |
title_sort |
can generic intravenous levetiracetam be used for acute repetitive convulsive seizure or status epilepticus? a randomized controlled trial |
publisher |
Adis, Springer Healthcare |
series |
Neurology and Therapy |
issn |
2193-8253 2193-6536 |
publishDate |
2019-08-01 |
description |
Abstract Introduction Intravenous levetiracetam (IV LEV) is approved for treatment status epilepticus (SE). However, the drug’s high cost must be considered when deciding on a treatment strategy. This study aimed to compare the efficacy of brand-name and generic IV LEV for acute repetitive convulsive seizure (ARCS) or SE. Methods Forty patients aged 18 years or older who had been diagnosed with SE or ARCS were included in this double-blind study. Patients were randomly assigned at a 1:1 ratio (via computer-generated code) to receive either brand-name or generic IV LEV. The primary outcomes were seizure control and the number of seizure exacerbations during the 24 h after drug administration, while the secondary outcomes were electroencephalographic (EEG) findings, serious adverse events, and clinical outcome at hospital discharge. Results Forty patients were randomly assigned administration with either brand-name IV LEV (10 SE and 10 ARCS patients) or generic IV LEV; 7 SE and 13 ARCS patients). There was no significant difference in patients’ baseline characteristics. The seizure control rate was 75% in the brand-name IV LEV group and 65% in the generic IV LEV group (p value: 0.490). Five (25%) patients in the brand-name IV LEV group, and six (30%) patients in the generic IV LEV group developed seizure exacerbations within 24 h after drug administration (p value 0.723). There were no reports of drug-related adverse events. Two of the patients taking brand-name IV LEV and one taking the generic IV LEV died (p value > 0.999). Conclusion Treatment with the generic IV LEV had comparable outcomes with brand-name IV LEV. The generic IV LEV may be an alternative medication for the treatment of SE and ARCS to reduce treatment costs. Trial Registration TCTR20190513001. Funding Great Eastern Drug Company. |
topic |
Acute repetitive seizures Levetiracetam Focale® Keppra® Status epilepticus |
url |
http://link.springer.com/article/10.1007/s40120-019-00150-x |
work_keys_str_mv |
AT rachotwongjirattikarn cangenericintravenouslevetiracetambeusedforacuterepetitiveconvulsiveseizureorstatusepilepticusarandomizedcontrolledtrial AT kittisaksawanyawisuth cangenericintravenouslevetiracetambeusedforacuterepetitiveconvulsiveseizureorstatusepilepticusarandomizedcontrolledtrial AT sineenardpranboon cangenericintravenouslevetiracetambeusedforacuterepetitiveconvulsiveseizureorstatusepilepticusarandomizedcontrolledtrial AT siriporntiamkao cangenericintravenouslevetiracetambeusedforacuterepetitiveconvulsiveseizureorstatusepilepticusarandomizedcontrolledtrial AT somsaktiamkao cangenericintravenouslevetiracetambeusedforacuterepetitiveconvulsiveseizureorstatusepilepticusarandomizedcontrolledtrial |
_version_ |
1724507303694041088 |